Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.

Next Previous
Trial Profile

Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary) ; Methylprednisolone; Methylprednisolone
  • Indications Cancer metastases; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 01 Feb 2012 Results published in the Bulletin du Cancer.
  • 13 Apr 2010 Planned end date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
  • 30 Mar 2010 Actual patient number (64) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top